All patients
Age < 65y (younger) Age > 65y cell type, non squamous cell cell type, squamous cell Gender, female Gender, male PD-L1 < 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), durvalumab plus tremelimumab vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.80 [0.61; 1.05]
MYSTIC (DT ; all population), 2020 0.94 [0.80; 1.11]
MYSTIC (DT ; PDL1>25%), 2020 0.85 [0.61; 1.18]
0.89 [0.78 ; 1.02 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 3 0% 1,361 moderate not evaluable progression or deaths (PFS)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.77 [0.59; 1.01]
MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.72; 1.53]
0.87 [0.65 ; 1.18 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 42% 617 moderate not evaluable objective responses (ORR)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 2.43 [1.05; 5.65]
MYSTIC (DT ; PDL1>25%), 2020 0.87 [0.55; 1.37]
1.36 [0.50 ; 3.70 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 77% 617 moderate not evaluable AE (any grade)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.59 [0.20; 1.69]
MYSTIC (DT ; all population), 2020 0.51 [0.27; 0.96]
MYSTIC (DT ; PDL1>25%), 2020 0.43 [0.15; 1.24]
0.50 [0.31 ; 0.82 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 3 0% 1,322 moderate not evaluable AE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.70 [0.43; 1.12]
MYSTIC (DT ; all population), 2020 1.02 [0.76; 1.37]
MYSTIC (DT ; PDL1>25%), 2020 0.86 [0.56; 1.35]
0.91 [0.73 ; 1.13 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 3 0% 1,322 moderate not evaluable AE leading to death (grade 5)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.41 [0.52; 3.82]
MYSTIC (DT ; all population), 2020 2.19 [1.17; 4.11]
MYSTIC (DT ; PDL1>25%), 2020 3.45 [1.24; 9.59]
2.19 [1.36 ; 3.51 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 3 0% 1,322 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.09 [0.58; 2.03]
MYSTIC (DT ; all population), 2020 1.43 [0.97; 2.10]
MYSTIC (DT ; PDL1>25%), 2020 1.63 [0.91; 2.93]
1.39 [1.05 ; 1.85 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 3 0% 1,322 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 2.14 [1.32; 3.47]
2.14 [1.32 ; 3.47 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable SAE (any grade)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.76 [1.04; 2.99]
MYSTIC (DT ; PDL1>25%), 2020 1.93 [1.22; 3.04]
1.86 [1.31 ; 2.62 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 0% 599 moderate not evaluable STRAE (any grade)detailed results MYSTIC (DT ; all population), 2020 1.52 [1.03; 2.24]
MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.59; 1.87]
1.35 [0.96 ; 1.89 ] MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 7% 1,039 moderate not evaluable STRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.43 [0.92; 2.21]
1.43 [0.92 ; 2.21 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable TRAE (any grade)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.39 [0.22; 0.69]
MYSTIC (DT ; all population), 2020 0.31 [0.22; 0.44]
MYSTIC (DT ; PDL1>25%), 2020 0.17 [0.09; 0.30]
0.28 [0.18 ; 0.43 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 3 56% 1,322 moderate not evaluable TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.49 [0.29; 0.84]
MYSTIC (DT ; all population), 2020 0.55 [0.39; 0.77]
MYSTIC (DT ; PDL1>25%), 2020 0.36 [0.22; 0.60]
0.49 [0.38 ; 0.62 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 3 0% 1,322 moderate not evaluable TRAE leading to death (grade 5)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
MYSTIC (DT ; all population), 2020 1.91 [0.47; 7.71]
MYSTIC (DT ; PDL1>25%), 2020 0.94 [0.06; 15.13]
1.52 [0.46 ; 4.98 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 3 0% 1,322 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.81 [0.81; 4.05]
MYSTIC (DT ; all population), 2020 1.47 [0.92; 2.35]
MYSTIC (DT ; PDL1>25%), 2020 1.04 [0.54; 2.03]
1.39 [0.99 ; 1.97 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 3 0% 1,322 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 2.95 [1.51; 5.78]
2.95 [1.51 ; 5.78 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
2.97 [0.31 ; 28.17 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Anaemia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.21 [0.02; 2.02]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19]
0.06 [0.00 ; 0.91 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 59% 1,006 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
MYSTIC (DT ; all population), 2020 0.06 [0.00; 1.01]
0.24 [0.01 ; 4.80 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 46% 1,006 moderate not evaluable Colitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 3.86 [0.19; 77.90]
MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
7.43 [0.93 ; 59.26 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Constipation TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.47 [0.02; 14.16]
0.47 [0.02 ; 14.16 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.09; 4.55]
MYSTIC (DT ; all population), 2020 0.95 [0.24; 3.82]
0.83 [0.27 ; 2.59 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.90 [0.06 ; 56.82 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 3.24 [0.37; 28.15]
MYSTIC (DT ; all population), 2020 4.35 [0.93; 20.28]
3.94 [1.13 ; 13.81 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Dyspnoea TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 2.56 [0.11; 57.33]
2.56 [0.11 ; 57.33 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Fatigue TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.47 [0.10; 2.13]
MYSTIC (DT ; all population), 2020 1.09 [0.39; 3.03]
0.83 [0.36 ; 1.95 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Hepatitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.92 [0.20; 18.73]
MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
4.15 [0.64 ; 26.90 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 8% 1,006 moderate not evaluable Hypersensitivity TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Hypertension TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.11; 14.23]
1.27 [0.11 ; 14.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.19 [0.09 ; 15.52 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.56 [0.14 ; 17.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
2.55 [0.24 ; 27.62 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
0.63 [0.01 ; 32.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.04; 10.24]
0.63 [0.04 ; 10.24 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
0.63 [0.01 ; 32.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
0.63 [0.01 ; 32.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.10 [0.01; 2.08]
0.10 [0.01 ; 2.08 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Myositis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
0.63 [0.01 ; 32.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Nausea TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
MYSTIC (DT ; all population), 2020 0.16 [0.02; 1.30]
0.21 [0.03 ; 1.38 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.03 [0.00; 0.45]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.20]
0.02 [0.00 ; 0.13 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 2.56 [0.11; 57.33]
2.56 [0.11 ; 57.33 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
0.63 [0.01 ; 32.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 6.52 [0.35; 120.50]
MYSTIC (DT ; all population), 2020 7.74 [0.96; 62.17]
7.30 [1.34 ; 39.79 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Pruritus TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.78 [0.05 ; 12.45 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.32 [0.01; 9.50]
0.32 [0.01 ; 9.50 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Rash TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.31 [0.03; 3.50]
MYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23]
0.51 [0.08 ; 3.12 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Stomatitis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.16 [0.01; 3.50]
MYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42]
0.06 [0.01 ; 0.46 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23]
0.63 [0.01 ; 32.23 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Vomiting TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 0.32 [0.01; 9.50]
MYSTIC (DT ; all population), 2020 0.07 [0.00; 1.18]
0.13 [0.01 ; 1.14 ] ARCTIC (DT ; study B ; PDL1<25%), 2020, MYSTIC (DT ; all population), 2020 2 0% 1,006 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results ARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28]
1.27 [0.04 ; 38.28 ] ARCTIC (DT ; study B ; PDL1<25%), 2020 1 0% 283 NA not evaluable Alopecia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Anaemia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.12 [0.05; 0.28]
0.12 [0.05 ; 0.28 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Asthenia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.86 [0.36; 2.05]
0.86 [0.36 ; 2.05 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Back pain AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.63 [0.10; 3.80]
0.63 [0.10 ; 3.80 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Constipation AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.90 [0.17; 21.07]
1.90 [0.17 ; 21.07 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Cough AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Decreased appetite AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.43 [0.40; 5.11]
1.43 [0.40 ; 5.11 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Diarrhoea AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 2.12 [0.73; 6.17]
2.12 [0.73 ; 6.17 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Dyspnoea AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.11 [0.37; 3.33]
1.11 [0.37 ; 3.33 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Fatigue AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.31 [0.52; 3.31]
1.31 [0.52 ; 3.31 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Nausea AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.63 [0.18; 2.25]
0.63 [0.18 ; 2.25 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Neutropenia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19]
0.01 [0.00 ; 0.19 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Pruritus AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Pyrexia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Rash AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23]
0.95 [0.06 ; 15.23 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42]
0.03 [0.00 ; 0.42 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Vomiting AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.13 [0.02; 1.09]
0.13 [0.02 ; 1.09 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Weight decreased AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 2.86 [0.30; 27.64]
2.86 [0.30 ; 27.64 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-29 16:42 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 634,861
